Table 4:
Parameter | Outcome |
---|---|
Median Duration of Therapy with: Temsirolimus Bevacizumab |
3.9 months 3.4 months |
Median Progression-Free Survival | 7.1 months (95% CI 4.6 – 8.7 months) |
Objective Response Rate | 2% (1 out of 48) |
Stable Disease Rate | 88% (42 out of 48) |